SCHEMBL6822058

SCHEMBL6822058

CCOc1ccn2nc(-c3ccccc3)c(-c3ccc(=O)n(C(C)C)n3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.42
PTGER1 P34995 1/20 0.38
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
IGF1R P08069 1/20 0.36
ADORA2A P29274 1/20 0.35
CASR P41180 1/20 0.35
CMKLR1 Q99788 1/20 0.35
TTK P33981 1/20 0.35
ABL1 P00519 2/20 0.35
SRC P12931 2/20 0.35
HCK P08631 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
EGFR P00533 1/20 0.34
LCK P06239 1/20 0.34
EPHA3 P29320 1/20 0.34
CSK P41240 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822546 0.92 ADORA1 (0.41) ADORA1IGF1RCASRCMKLR1ABL1
SCHEMBL6822608 0.90 CMKLR1 (0.41) ADORA1CMKLR1ABL1SRC
SCHEMBL6824716 0.90 ADORA1 (0.40) ADORA1IGF1RADORA2ACMKLR1HRH3
SCHEMBL6818520 0.90 ADORA1 (0.40) ADORA1IGF1RADORA2ACMKLR1HRH3
SCHEMBL6818702 0.90 ADORA1 (0.46) ADORA1CMKLR1
SCHEMBL6821959 0.89 ADORA1 (0.42) ADORA1PTGER1IGF1RCASREGFR
SCHEMBL6822276 0.89 ADORA1 (0.46) ADORA1TP53POLBIGF1RCMKLR1
SCHEMBL6822100 0.89 ADORA1 (0.40) ADORA1IGF1RCMKLR1HRH3
SCHEMBL6822034 0.89 NPC1 (0.42) ADORA1PTGER1LMNACMKLR1
SCHEMBL6822138 0.88 ADORA1 (0.45) ADORA1ADORA2ASRCHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 ADORA1 22/4885PTGER1 325/4885LMNA 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.